Behind 13,000 Reported Cases
Oropouche Fever and the Risk to Pregnancy

← Back to Latin America News

A fever, a headache, gone in a few days. There is an illness long treated as exactly that kind of "nothing-much fever": Oropouche. Yet when the 2023 South American outbreak was re-examined, just 13,000 cases were confirmed while actual infections were estimated at about 9.4 million. A gap of more than 700-fold. And with transmission from mother to fetus now confirmed, it is no longer just a fever.

A Fever Carried by Midges, Not Mosquitoes

Oropouche virus was first identified in 1955, in the Brazilian Amazon. Dengue and Zika are carried by mosquitoes, but the main vector here is the midge, a tiny biting insect. The different route means mosquito control alone cannot stop it. Symptoms are fever, headache, muscle pain and light sensitivity, usually resolving on their own within one to two weeks. Which is precisely why it has been overlooked.

What a 700-Fold Gap Means

The turning point was a flare-up in Brazil's Amazonas state in late 2023. In 2024 it spread to Bolivia, Colombia, Cuba, Guyana, Peru and the Dominican Republic. PAHO counted 13,014 confirmed cases as of December 2024. Yet a 2026 study in Nature Medicine, drawing on a population survey in the state capital Manaus, estimated actual infections at about 9.4 million. In Manaus, the share of people carrying antibodies to the virus rose from 11.4% in November 2023 to 25.7% just a year later — meaning one in four residents had been infected without ever being reported.

It Recalls "the Zika Years"

Alarm rose sharply because, from July 2024, infections in pregnant women were reported to reach the fetus through the placenta, leading to stillbirth and microcephaly. Many will recall the Zika fever that struck South America in 2015-16. The children born then with congenital conditions, microcephaly among them, numbered in the thousands. Whether Oropouche reaches that scale is not yet known. But to keep calling it a mild fever and stand unguarded would risk the same path. In 2024, the first adult deaths were also reported.

From the View of an Assistive-Device and Disability-Policy Researcher

What weighs on me is less the outbreak than its aftermath. After Zika, the delivery of rehabilitation and assistive devices to children with microcephaly varied sharply by region in Brazil. There were towns where it arrived and villages where, after half a year, it did not. Having watched the realities of orthotics in Costa Rica, I cannot treat this as someone else's problem. Congenital disability stays with a child and family for a decade or more after the virus is gone. So the real question is less about counting infections than whether a system exists to deliver early, uninterrupted support to the children being born — the deeper strength of a health system.

There is, at present, no approved vaccine or specific drug for Oropouche. Prevention rests on reducing contact with the insect vector. Midges breed easily in the organic-rich environments of the Amazon, and deforestation brings their habitat closer to where people live. Climate change, too, is not unrelated to where insects spread. Disease, environment and disability policy look like separate stories, yet they connect over the same river basin.

Trust the figure of 13,000 and you will be too late for the next outbreak. The risk to children yet to be born hides on the side that was never counted.

※ This article is the author’s commentary based on public information. Please confirm the latest figures, dates and procedures with governments and primary sources. Quotations are kept minimal and sources are cited.